MedPath

Comparison of NN5401 with insulin glargine, both in combination with oral antidiabetic drugs, in subjects with type 2 diabetes

Phase 3
Completed
Conditions
Diabetes mellitus, Diabetes Mellitus, Type 2.,
Registration Number
CTRI/2010/091/000022
Lead Sponsor
Novo Nordisk AS
Brief Summary

The aim of this clinical trial is to compare NN5401 with insulin glargine in patients with type 2 diabetes inadequately controlled with insulin and oral antidiabetic drugs (OADs). Subjects will continue their ongoing treatment with OADs (oral anti-diabetic drugs) in the trial.Trial ID: NN5401-3593No of subjects enrolled in India: Randomised: 108First patient first Visit:04 Mar 2010

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
450
Inclusion Criteria
  • Type 2 diabetes mellitus for at least 6 months Ongoing daily treatment with a basal insulin (insulin detemir, insulin glargine, or insulin NPH) once daily for at least 3 months Ongoing treatment with metformin with our without other OADs (oral anti-diabetic drugs) for at least 3 months HbA1c 7.0 ?
  • 10.0 % (both inclusive) BMI (Body Mass Index) at most 40.0 kg/m2 Age 18 Years and older.
Exclusion Criteria

Treatment with other insulin regimens than those listed in key inclusion criterion within the last 3 months Treatment with rosiglitazone, or GLP-1 receptor agonists within the last 3 months Significant cardiovascular disease within the last 6 months Uncontrolled treated/untreated severe hypertension Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures Impaired liver or renal function Cancer and medical history of cancer.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
HbA1c change from baselineAfter 26 weeks of treatment.
Secondary Outcome Measures
NameTimeMethod
Plasma glucose profilesAfter 26 weeks of treatment

Trial Locations

Locations (9)

Belgaum Diabetes Centre

🇮🇳

Belgaum, KARNATAKA, India

Centre for Diabetes and Endocrine Diseases

🇮🇳

apartment,Swaroop, India

Dia Care

🇮🇳

Ahmadabad, GUJARAT, India

Diabetes Care Centre

🇮🇳

Thiruvananthapuram, KERALA, India

Kanungo Institute of Diabetes Specialities Pvt Ltd,

🇮🇳

Plot, No:1120,,Dumduma,, India

KMC Hospital

🇮🇳

Bangalore, KARNATAKA, India

Life Care Clinic & Research Centre

🇮🇳

Bangalore, KARNATAKA, India

Osmania General Hospital,

🇮🇳

Hyderabad, ANDHRA PRADESH, India

Sahyadri Hospital

🇮🇳

Pune, MAHARASHTRA, India

Belgaum Diabetes Centre
🇮🇳Belgaum, KARNATAKA, India
Dr.Neetha Deshpande
Principal investigator
919880271313
neetarohit@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.